--- title: "SILEXION THERAPEUTICS CORP C/WTS EXP 15/08/2029 (TO PUR COM) | 8-K: FY2026 Q1 Revenue: USD 0" type: "News" locale: "en" url: "https://longbridge.com/en/news/286771849.md" datetime: "2026-05-18T12:35:24.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/286771849.md) - [en](https://longbridge.com/en/news/286771849.md) - [zh-HK](https://longbridge.com/zh-HK/news/286771849.md) --- # SILEXION THERAPEUTICS CORP C/WTS EXP 15/08/2029 (TO PUR COM) | 8-K: FY2026 Q1 Revenue: USD 0 Revenue: As of FY2026 Q1, the actual value is USD 0. EPS: As of FY2026 Q1, the actual value is USD -0.85. EBIT: As of FY2026 Q1, the actual value is USD -2.749 M. All figures are in thousands of U.S. dollars unless otherwise specified . #### Operational Metrics - **Research and Development (R&D) Expenses**: - For the three months ended March 31, 2026, R&D expenses were $1,370, marking a 133.3% increase compared to $590 for the same period in 2025 . This rise was primarily due to higher subcontractor and consultant expenses related to toxicology studies, product development, and GMP manufacturing, alongside non-cash share-based compensation expenses . - **General and Administrative (G&A) Expenses**: - G&A expenses were $1,379 for the three months ended March 31, 2026, an increase of 27.3% from $1,060 in the prior year’s period . This increase was mainly driven by higher professional services costs and non-cash share-based compensation expenses . - **Total Operating Expenses**: - Total operating expenses for the three months ended March 31, 2026, reached $2,749, up from $1,650 for the same period in 2025 . - **Operating Loss**: - The operating loss for the three months ended March 31, 2026, was $2,749, compared to $1,650 for the same period in 2025 . - **Financial Expense (Income), Net**: - The company reported a financial income, net of -$16 for the three months ended March 31, 2026, a change from a financial expense of $85 for the same period in 2025 . - **Net Loss**: - The net loss for the three months ended March 31, 2026, was $2,733, an increase of 58.8% from $1,735 for the same period in 2025 . This was primarily due to higher R&D and G&A expenses . - **Loss Per Share, Basic and Diluted**: - Loss per share was $0.85 for the three months ended March 31, 2026, compared to $3.84 for the same period in 2025 . - **Weighted Average Number of Ordinary Shares Outstanding**: - The weighted average number of ordinary shares outstanding was 3,230,378 for the three months ended March 31, 2026, significantly higher than 451,990 for the same period in 2025 . #### Balance Sheet Highlights - **Cash and Cash Equivalents**: - Cash and cash equivalents stood at $2,413 as of March 31, 2026, a decrease from $5,991 as of December 31, 2025 . This decline reflects ongoing operating expenses for preclinical and clinical readiness activities . - **Total Current Assets**: - Total current assets were $4,065 as of March 31, 2026, down from $6,637 as of December 31, 2025 . - **Total Assets**: - Total assets were $4,602 as of March 31, 2026, compared to $7,215 as of December 31, 2025 . - **Total Current Liabilities**: - Total current liabilities were $4,060 as of March 31, 2026, an increase from $2,758 as of December 31, 2025 . - **Total Liabilities**: - Total liabilities were $4,311 as of March 31, 2026, compared to $4,612 as of December 31, 2025 . - **Total Shareholders’ Equity (Capital Deficiency)**: - Total shareholders’ equity was $291 as of March 31, 2026, a decrease from $2,603 as of December 31, 2025 . - **Subsequent Capital Raising**: - Subsequent to quarter-end, Silexion Therapeutics Corp. generated approximately $1,000 in gross proceeds through a May 2026 warrant exercise inducement transaction and utilization of its at-the-market facility . These actions have raised the company’s shareholders’ equity above the $2,500 minimum required for Nasdaq Capital Market continued listing . #### Outlook / Guidance Silexion Therapeutics Corp. expects to initiate its Phase 2⁄3 clinical trial of SIL204 in locally advanced pancreatic cancer in the second quarter of 2026, pending regulatory approvals in Israel and Germany . The study is planned for leading oncology centers across Germany, additional EU member states, and Israeli sites . The company continues to evaluate financing alternatives to support the advancement of SIL204 into clinical trials . ### Related Stocks - [SLXNW.US](https://longbridge.com/en/quote/SLXNW.US.md) ## Related News & Research - [The Home Depot Announces First Quarter Fiscal 2026 Results; Reaffirms Fiscal 2026 Guidance | HD Stock News](https://longbridge.com/en/news/286890512.md) - [ONWARD Medical to Announce First Quarter 2026 Results on May 26, 2026 | ONWRY Stock News](https://longbridge.com/en/news/286858298.md) - [Autohome Inc. to Announce First Quarter 2026 Financial Results on May 28, 2026 | ATHM Stock News](https://longbridge.com/en/news/286390966.md) - [Keysight Technologies Reports Second Quarter 2026 Results | KEYS Stock News](https://longbridge.com/en/news/286959830.md) - [Correction: NextNRG to Host First Quarter 2026 Financial Results Conference Call on May 18, 2026 at 9:00 a.m. ET | NXXT Stock News](https://longbridge.com/en/news/286673001.md)